Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Alternative Names: CTI-085; INM 085

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals; University of Debrecen
  • Class Cannabinoids; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hypersensitivity
  • No development reported Glaucoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Glaucoma in Canada (Ophthalmic, Drops)
  • 14 May 2018 InMed Pharmaceuticals files a Patent Cooperation Treaty application for CTI-085
  • 12 Sep 2017 InMed Pharmaceuticals files provisional patent application with US Patent and Trademark Office for E. coli-based expression system for biosynthesis of cannabinoids in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top